Stock Events

Stock Events

Benitec Biopharma 

$12.15
19
+$0.35+2.97% Thursday 20:00

Statistics

Day High
12.33
Day Low
11.87
52W High
16.76
52W Low
9.85
Volume
154,627
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

14MayExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Q1 2026
-0.78
-0.59
-0.41
-0.22
Expected EPS
-0.268333
Actual EPS
-0.24

Financials

-24,942.47%Profit Margin
Unprofitable
2017
2018
2019
2020
2021
2022
73,000Revenue
-18.21MNet Income

Analyst Ratings

28.50Average Price Target
The highest estimate is 32.00.
From 2 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow BNTC. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Alnylam Pharmaceuticals
ALNY
Mkt Cap37.76B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, directly competing with Benitec's gene-silencing technologies.
Ionis Pharmaceuticals
IONS
Mkt Cap12.11B
Ionis Pharmaceuticals focuses on RNA-targeted drug discovery and development, making it a direct competitor in the RNA-based therapeutic space.
Arrowhead Pharmaceuticals
ARWR
Mkt Cap10.5B
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them, competing in the same gene-silencing niche.
Sarepta Therapeutics
SRPT
Mkt Cap1.62B
Sarepta Therapeutics is involved in genetic modulation, including RNA-targeted therapies, positioning it as a competitor in genetic disease treatment.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.81B
BioMarin Pharmaceutical focuses on enzyme replacement therapies and other genetic disease treatments, overlapping with Benitec's target market.
Sangamo Therapeutics
SGMO
Mkt Cap62.14M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and gene regulation, competing in the broader genetic treatment market.
CRISPR Therapeutics
CRSP
Mkt Cap4.9B
CRISPR Therapeutics is engaged in gene editing, a different but competing approach to treating genetic diseases compared to Benitec's gene-silencing.
Editas Medicine
EDIT
Mkt Cap383.65M
Editas Medicine operates in the gene editing space, specifically CRISPR, offering alternative genetic disease treatments.
Intellia Therapeutics
NTLA
Mkt Cap1.69B
Intellia Therapeutics is another key player in CRISPR-based gene editing, providing competitive technologies for genetic disease treatment.

About

Benitec Biopharma Inc. is an emerging biotechnology firm dedicated to advancing groundbreaking genetic medicines. The company specializes in DNA-directed RNA interference (RNAi) based treatments, which it develops to address severe and enduring human conditions. Its pipeline features BB-301, an adeno-associated virus (AAV) gene therapy aimed at treating oculopharyngeal muscular dystrophy, and BB-103, designed to combat chronic hepatitis B virus infection. Established in 1995, Benitec Biopharma's main operations are situated in Hayward, California.
Show more...
CEO
Dr. Jerel A. Banks M.D., Ph.D.
Employees
16
Country
United States
ISIN
US08205P2092

Listings

MU
DE
BJ93.MU
STU
DE
BJ93.STU
XNAS
US
BNTC
BOATS
BOATS
BNTC.BOATS

0 Comments

Share your thoughts

FAQ

What is Benitec Biopharma stock price today?▼
The current price of BNTC is $12.15 USD — it has increased by +2.97% in the past 24 hours. Watch Benitec Biopharma stock price performance more closely on the chart.
What is Benitec Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Benitec Biopharma stocks are traded under the ticker BNTC.
Is Benitec Biopharma stock price growing?▼
BNTC stock has risen by +8.68% compared to the previous week, the month change is a +10.56% rise, over the last year Benitec Biopharma has showed a -16.84% decrease.
When is the next Benitec Biopharma earnings date?▼
Benitec Biopharma is going to release the next earnings report on September 30, 2026.
What were Benitec Biopharma earnings last quarter?▼
BNTC earnings for the last quarter are -0.24 USD per share, whereas the estimation was -0.27 USD resulting in a +10.56% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Benitec Biopharma revenue for the last year?▼
Benitec Biopharma revenue for the last year amounts to 73,000 USD.
What is Benitec Biopharma net income for the last year?▼
BNTC net income for the last year is -18.21M USD.
How many employees does Benitec Biopharma have?▼
As of June 20, 2026, the company has 16 employees.
In which sector is Benitec Biopharma located?▼
Benitec Biopharma operates in the Health & Wellness sector.
When did Benitec Biopharma complete a stock split?▼
The last stock split for Benitec Biopharma was on July 26, 2023 with a ratio of 1:17.
Where is Benitec Biopharma headquartered?▼
Benitec Biopharma is headquartered in Hayward, United States.